Crowds spill onto New York streets and block traffic to catch glimpse of 'Manhattanhenge' sunset
"Manhattanhenge" occurs when the Sun perfectly aligns with the borough's street grid and sinks below the horizon, framed by a canyon of skyscrapers.
Sidewalks and parks were packed to watch the unique sunset on Thursday, local time, which occurs on a handful of spring and summer evenings.
The first Manhattanhenge of the year took place on Wednesday evening, but was repeated again on Thursday.
Thursday's sunset was briefly visible, but mostly blocked by clouds.
It will occur again on July 11 and 12.
Astrophysicist Neil deGrasse Tyson coined the term in an article published in the National History magazine in 1997.
The future television host was part of an expedition led by Gerald Hawkins, the scientist who first theorised that Stonehenge was constructed as an ancient astronomical observatory.
It struck Dr Tyson, who is a New York local, that the biannual sunset alignment that occurs in Manhattan could be compared to the Sun's rays striking the centre of the Stonehenge circle on the summer solstice.
The summer solstice is an annual event that refers to when a hemisphere experiences its longest stretch of daylight over a 24-hour period.
Manhattanhenge doesn't take place on the summer solstice itself, though.
The two events are separated by about three weeks before and after the solstice.
AP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
11 hours ago
- News.com.au
Review: Was the newest Jurassic Park sequel really necessary?
With the welcome return of those stomping, chomping dinosaurs and another hitout for AI avenger M3GAN, there's scares aplenty on the big screen this week JURASSIC WORLD REBIRTH (M) Starring: Scarlett Johansson, Mahershala Ali, Rupert Friend. Same fight, with more convincing bite With Jurassic World Rebirth we reach instalment number seven in the lucrative series spawned by Steven Spielberg's 1993 dinos-on-the-rampage classic Jurassic Park. We know enough by now to acknowledge that first blockbuster breakthrough will never be bettered. The formula that keeps serving up humans as possible snacks for prehistoric predators just doesn't allow the wiggle room for expansion or variation. Therefore the filmmakers are compelled to relentlessly double-down on the authenticity of the action scenes. And it is in this one department that Rebirth truly excels. When the stompin' and the chompin' commences, you will be daunted and intimidated in thoroughly convincing fashion. Just bear in mind that aside from an early dino-centric feast – after a scientist ill-advisedly drops a chocolate-bar wrapper in his lab – there is something of a wait to be endured before Rebirth gets busy with the good stuff. Much of the first hour is spent mulching copious amounts of set-up and exposition as we get to know who will be edging towards and running from the gnarly stars of the show. The most prominent players in proceedings are Zora (Scarlett Johansson) and Duncan (Mahershala Ali), two good buddies who have parlayed a past in military special-ops into a shady side-hustle doing the same kind of thing for major corporations. Zora, Duncan and a mixed bag of lesser lights gradually find themselves on a secret assignment to an equatorial zone that (after the ravages posed by climate change) is now the only place on the planet that dinosaurs can feasibly survive. The principal task of this mob is to extract select strains of dino DNA from three different species so that a dodgy pharmaceutical boss (Rupert Friend) can roll out a suite of miracle drugs for billions of bucks. To be frank, the storylines traversed by Rebirth (which are the work of Jurassic Park's original screenwriter David Koepp) lead nowhere in particular, and do not exactly have you rooting for the survival or otherwise of any one character. However, once the fates conspire to have the entire cast stranded on a remote island, director Garth Edwards lets rip with a steady supply of truly exciting set pieces awash with both genuine aggression and vivid atmosphere. On a technical level, the lighting and cinematography standards on display during the special-effects sequences are next-level great, and deserve to be witnessed on the biggest screen available. Jurassic Park Rebirth is in cinemas now M3GAN 2.0 (MA15+) General release The babysitting bot who turned out to be an AI-powered equivalent of Annabelle is back. Only this time – like Arnie In Terminator 2 – the once-dreaded doll M3GAN just might be fighting for a greater good. If you remember the first movie (a major hit a few years ago), you will recall that M3GAN's sinister software was eventually deactivated on account of sustained bad behaviour and a body count that hit triple figures. Now she has been reluctantly switched on once more by her long-suffering programmer Gemma (Alison Williams) to combat the deadly threat posed by the new AI assassin AMELIA (aka Autonomous Military Engagement Logistics and Infiltration Android). Some long-overdue coding modifications for the title character means she can renew her over-protective relationship with Gemma's teenage niece Cady (Violet McGraw). This sequel is at its strongest when playing strictly for ridiculous laughs instead of creepy chills, and for the most part, its desire to jauntily jolt its audience is effectively completed. Not sure they should go to the well a third time, however. RIVIERA REVENGE (PG) Selected cinemas While it is getting continually more difficult getting a Hollywood comedy made and released these days, the love of the French for laughs with a lightness of touch remains undiminished. Yes, most of them are as unsurprising as they are inoffensive. Nevertheless, the better ones pay their way courtesy of good casting chemistry and attractive production. So proves to be the case for Riviera Revenge, a concoction as fluffy as a souffle, but not without its bursts of sweetly addictive flavour. Veteran star Andre Dussolier plays Francois, a retired military general who finds himself waging a whole new battle late in life when he suspects his beloved wife of 40 years (a wonderful Sabine Azema) may once have had an affair with a mutual friend (Thierry Lhermitte). Some decent chuckles are earned the right way here thanks largely to the lively lead performers, and the sun-dappled coastline of the Cote D'Azur looks as stunning as ever.
ABC News
12 hours ago
- ABC News
From photos to fitness data, recording our lives is changing how our brains work
Do you have more photos on your phone than you know what to do with? Apart from taking up valuable space, experts have another reason why you should think twice before whipping your phone out to capture that special moment. Taking photos might actually make it harder to recall the very thing you want to remember. Over the past two decades, researchers have been teasing out how a steep increase in "lifelogging" influences how we think, act and make sense of our past. Julia Soares, who studies the impact of digital technologies on memory at Mississippi State University, has identified several areas where our digital devices affect how our brain works. An overstuffed photo app might be just the beginning of a profound cognitive shift. Lifelogging involves digitally recording aspects of your daily life: things like photos as well as fitness, travel and health metrics. Dr Soares says such data collection may have benefit — a number of studies have found it can help support memory recall and quality of life — but it depends on how intentional someone is about analysing and reviewing their data. "I have a couple of studies where we've found that taking photos can impair memory," Dr Soares says. "So your memory specifically for objects that you photographed compared to objects that you don't photograph." This phenomenon — called the "photo-taking-impairment effect" — has been demonstrated multiple times in a particular type of experiment. Imagine two groups of people at the entrance to an art museum, about to wander through. One group is instructed to take photographs of the artworks they see, while the other group is told to take no photographs at all. Once they're done walking through the museum, the two groups are quizzed about visual details of the artworks they've looked at, like whether the Moon in Vincent Van Gogh's The Starry Night is full or a crescent. In multiple different versions of this experiment, scientists have observed that people who don't take photos tend to have better recall for what they've seen. They get more questions right about the visual details of the artworks compared to the photo-taking group. It's not fully clear why those who take more photographs in these experiments tend to remember less, Dr Soares says. Down the track, when photographs are used as a prompt to help people remember, they can be a "highly effective memory cue". But it may be that in the moment, the act of taking the photograph distracts somebody from fully capturing the event in their internal memory. This research has influenced how Dr Soares herself takes photographs. "I do try to make sure that when I take a photo, I'm in the mindset of thinking, 'How is this going to cue my retrieval later on?' It should be something that I want to remember alongside the photo." It's not just our visual memories that we're outsourcing by snapping them on our phones. There are also fitness and biometric tracking, voice memos, emails, travel data and chat logs. Dr Soares says if all this information isn't used deliberately, people can just end up with pointless piles of data. "If you're not paying attention to the data, then it just collects up." But used well, lifelogging can also be a powerful too help us make positive behaviour changes. "You can come to some really useful insights by collecting all of this data," she says. Kunal Kalro began recording his health data more than a decade ago after his father died from heart disease. Kunal started out tracking his daily step count and workouts using a fitness band. Before long he was also collecting heart rate variability, temperature, sleep quality and even macronutrient intake. "It helps you change your behaviour patterns," says the 38-year-old, who still tracks his health data today. "If you're having a few nights of poor sleep because you're watching a TV show late at night … you see your daily scores fall. He says tracking his data has helped him uncover patterns of behaviour he wasn't aware of, like the relationship between his coffee consumption and sleep. "I can notice and I will see the difference in my heart rate variability overnight when I'm sleeping if I've had caffeine after midday versus before," he says. "For me anyway, it's less about memory recall, but more about making something a little bit more consciously present. I feel way more in sync with my body." Lifelogging on our smart devices isn't the only way our seemingly instant access to digital technology is changing our ability to think and recall. Dr Soares has also looked at what we think we know, which is influenced by search engines such as Google and the ability to save and search up information on our devices. She says there is evidence to show that people can overestimate what they know after using the internet, and fail to distinguish between the knowledge in their head and the knowledge that they can access with search engines. In some experiments, researchers found search engine use during a quiz led to an increase in "cognitive self-esteem" — an increased belief in one's own ability to remember information and perform well on future quizzes. "Even if they ask them really carefully, 'What do you know? What is in your brain?', people can sometimes overestimate what they know as a result of using internet search," Dr Soares says. Despite the evidence that snapping photos can negatively affect our memories, and that having Google in our pocket is distorting our sense of our own knowledge, Dr Soares doesn't think you should throw your phone away. "These digital technologies that take off clearly have some type of utility for people," she says. "But [we need to] inform people about the ways to effectively use these technologies alongside their cognitive system." Listen to the full episode of Brain Rot about life-logging and its effects, and follow the podcast for more.
News.com.au
19 hours ago
- News.com.au
Biocurious: Dimerix could be riding big and beautiful kidney drug success earlier than expected
With the FDA's blessing, Dimerix will use phase III trial endpoints that could lead to accelerated approval for its kidney disease drug Dimerix is confident of phase III success because an expert 'peek' at the blinded data shows it's on the right track The company is well cashed up, courtesy of four global distribution deals When it comes to clinical trials, the choice of primary endpoints can mean the difference between a trial failing and a billion-dollar blockbuster drug emerging. Plenty of drug candidates have looked successful at mid stage, but then floundered because a later stage trial has failed to meet strictly defined goals. This appears to be the case with Opthea (ASX:OPT) and the recent failure of its two phase III eye disease trials. In other cases, strictly enforced endpoints mean that a trial is too long and too expensive. But regulatory attitudes are changing. In the case of Dimerix (ASX:DXB), the US Food & Drug Administration (FDA) has delivered the kidney disease drug developer a concession on endpoints for its ongoing phase III trial. The FDA's stance not only means that the endpoints are more likely to be achieved, reducing risk. It also means the company could win accelerated FDA marketing approval before the study has completed. 'That sparked a lot of interest in the sector because suddenly the trials are more manageable,' says Dimerix chief Dr Nina Webster. The 286-patient study is testing Dimerix's candidate DMX-200 for the regressive focal segmental glomerulosclerosis (FSGS). A rare – but not ultra rare – disease, FSGS usually results in end-stage kidney failure. Endpoints have delayed the endgame Previously, the FDA had set an endpoint of how well a drug preserves kidney function. But this meant a trial had to track the patient to kidney failure or death, which could take years. This makes a trial too long and too costly. 'In rare diseases, no-one is going to do these studies,' Webster says. About five years ago the FDA became more amenable to the use of 'surrogate' endpoints These are measures that substitute a true clinical endpoint to expedite drug development. The FDA allowed the use of the kidney function biomarker, called estimated global filtration rate (eGFR). Under the dainty banner of 'Parasol' – and, no it's not an umbrella group – experts advised the use of proteinuria as a further alternative endpoint for FSGS. Proteinuria is kidney proteins seeping into the urine, while eGFR is the rate at which the spuds can cleanse blood. If proteinuria is present and the eGFR is not up to scratch, they are sure signs the kidneys are not working as they should. Conversely, if a drug reduces proteinuria or the eGFR 'slope rate' – the rate of decline – it is accepted as being effective. Parasol promises faster Action Dubbed Action 3, the Dimerix trial involves two years' treatment, as measured against placebo. The study is due to complete in 2027 when the last patients have been treated. But Dimerix now is working with Parasol to establish the exact surrogate endpoints required to front the FDA for accelerated marketing approval. Expedited approval is as allowed for some orphan drugs, such as DMX-200. 'The full study is for two years and that doesn't change,' Webster says. 'Th question is whether we can get interim approval and go to market earlier.' One possibility is that proteinuria alone could be the accepted endpoint, given proteinuria and eGFR appear to point to the same thing. That is: deteriorating kidneys. Dr Webster says an accelerated endpoint must reasonably predict the outcome of the trial. 'The question is, what do we need to see at point X to prove the end at point Y? Parasol is working with us on that. 'We're collecting all of our data on eGFR and proteinuria anyway, so it gives us a lot of flexibility in the program.' (Other geographies such as Japan and Europe still require an eGFR endpoint). Surrogate change spurs others … The FDA's stance on surrogate endpoints could be a double-edged sword for Dimerix, as it also provides succour to potential rivals. In this vein, a drug called sparsentan (brand name Filspari ) won FDA approval for a kidney condition called IgA nephropathy. The drug failed its Phase III endpoint for eGFR. But now its owner Travere Therapeutics is having a crack at FDA marketing approval for FSGS using a proteinuria endpoint. The data from the supportive trial was unblinded, which means the study custodians can't change the endpoints retrospectively. 'But the FDA is in a hard spot with this one because is an area of such high unmet need,' Webster says. 'These patients currently have limited treatment options and Filspari looks like it is doing something for them. 'We are waiting with bated breath in the hope that Filspari is approved and gives hope to these patients.' Travere has licensed the European and local sparsentan rights to our own CSL (ASX:CSL). … but we're friends, not rivals Webster says rather than rivalling DMX-200, sparsentan could be used in unison. An angiotensin receptor, sparsentan targets high blood pressure – a key cause of kidney disease in the first place. (High blood pressure causes inflammation which causes scarring and cell death). Thus, sparsentan needs to be better than the current blood pressure medication. But DMX-200 works on the secondary inflammatory pathway, with the patients already on blood pressure meds. 'It's not apples for apples with study design, which is why we are compared against the placebo and not a comparator,' Webster says. In effect, DMX-200 faces a lower comparative hurdle. 'Our drug is complementary, not competitive,' Webster says. Data 'peek' hints at trial success While a trial result is never certain, Dimerix is confident it won't meet the fate of Opthea or Percheron Therapeutics (ASX:PER). (The latter's neurological disease trial also failed to meet primary endpoints). One reason is that the Action 3 trial already has been subject to a blinded interim analysis by an arm's length expert committee, which peeked at the data. 'Blinded' means that Dimerix, the trial investigators and the patients don't know the results. In March last year the 72-patient analysis reported that DMX-200 worked better than placebo. As per protocol, the experts did not disclose the extent of this efficacy. But it was enough for the company to know that it's on the right track. 'We just know at that point in time, we were doing better and that if we carry on that trajectory, we have a shot at the endpoint,' Webster says. 'That was a big moment for us, because we wanted to confirm something similar to our smaller phase II study in a larger cohort of patients.' FDA approval could come sooner rather than later Dimerix has received over $65 million of cash, courtesy of four distribution deals that may deliver up to $1.4 billion of milestone payments plus royalties. While a further capital raising is a case of 'never say never', it's unlikely. Naturally, most of the milestones are back ended to achievements such as phase III success and FDA approval. But with accelerated approval possible after the interim analysis, the latter might be sooner than investors think. Many drug developers view the Trump Ascendancy Mark Two with trepidation. In contrast, Webster notes Trump nominated kidney disease as a key health priority in his first stab at POTUS. The financial motive alone is compelling, in that dialysis costs the US health system around US$125 billion annually. 'We are in the sweet spot of being a rare disease (with pricing benefits) and having the potential to reduce US healthcare costs,' Webster says.
